No label defined (Q3696915)

From EU Knowledge Graph
Revision as of 10:43, 22 November 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Clinical molecular imaging and in particular Positons Emission Tomography (TEP) is taking on a growing role in medicine, particularly in major public health areas such as oncology, neurology, and cardiovascular disease. Molecular imaging techniques, along with biology, have improved diagnosis, define the most appropriate treatments and evaluate their therapeutic effectiveness for each patient. The significant potential of this technology, in par...)
Jump to navigation Jump to search
Project Q3696915 in France
Language Label Description Also known as
English
No label defined
Project Q3696915 in France

    Statements

    0 references
    556,394.0 Euro
    0 references
    2,271,948.0 Euro
    0 references
    24.49 percent
    0 references
    1 January 2016
    0 references
    30 June 2018
    0 references
    NANCYCLOTEP
    0 references
    L’imagerie moléculaire clinique et en particulier la Tomographie par Emission de Positons (TEP) prend une place croissante en médecine, et en particulier dans les grands domaines de santé publique tels que l’oncologie, la neurologie, et les maladies cardiovasculaires. Les techniques d’imagerie moléculaire ont permis, avec la biologie, d’améliorer le diagnostic, de définir les traitements les mieux adaptés et d’en évaluer l’efficacité thérapeutique pour chaque patient. Le potentiel significatif de cette technologie, en particulier avec les très nombreux traceurs dont l’intérêt médical est validé dans la littérature ou par l’usage dans d’autres centres européens, n’est actuellement pas suffisamment exploité en clinique du fait des contraintes techniques, logistiques, organisationnelles et économiques, liées à la courte demi-vie de ces radiotraceurs et à la complexité réglementaire de leur mise en œuvre. (French)
    0 references
    Clinical molecular imaging and in particular Positons Emission Tomography (TEP) is taking on a growing role in medicine, particularly in major public health areas such as oncology, neurology, and cardiovascular disease. Molecular imaging techniques, along with biology, have improved diagnosis, define the most appropriate treatments and evaluate their therapeutic effectiveness for each patient. The significant potential of this technology, in particular with the very many tracers whose medical interest is validated in the literature or by use in other European centres, is currently not sufficiently exploited in clinics due to the technical, logistical, organisational and economic constraints associated with the short half-life of these radiotracers and the regulatory complexity of their implementation. (English)
    22 November 2021
    0 references

    Identifiers

    LO0007814
    0 references